Status:
COMPLETED
Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome
Lead Sponsor:
National Hepatology & Tropical Medicine Research Institute
Conditions:
Hepato-Renal Syndrome
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Hepatorenal syndrome is a functional renal impairment occurring in cirrhotic patients . It develops secondary to splanchnic arterial vasodilatation which decreases the effective blood volume, activate...
Eligibility Criteria
Inclusion
- Both sexes aged 18 years or older having cirrhosis, ascites, and a diagnosis of HRS-AKI based on the 2015 International Club of Ascites (ICA) diagnostic criteria
Exclusion
- Serum creatinine (sCr) \>7 mg/dL Hypotension (mean arterial pressure (MAP) \<70 mm Hg) or sepsis. Recent treatment with vasopressors. Patients with severe cardiovascular disease Known allergy to study medications
Key Trial Info
Start Date :
April 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 23 2020
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT04522297
Start Date
April 15 2018
End Date
January 23 2020
Last Update
August 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The National Hepatology and Tropical Research medicine institute
Cairo, Egypt